Pancreatic Cancer Research

Clinical trialNo phase (not a drug trial)Withdrawn

A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis(SHR-1210-HLJ-009)

Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis: a Single-arm, Prospective Study

Outcome
Stopped earlyFailed to pass ethics committee review (Other)
Phase
No phase (not a drug trial)
Status
Withdrawn
Study type
Interventional
Planned start
1 August 2020
Planned end
1 August 2023
Enrollment
0 participants
Sites
0
Primary outcomes
6-month PFS rate
Sponsor type
Academic / other
Results posted
No
Last update
4 October 2022

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This is a a single-arm, prospective study of Camrelizumab combined with ablation and chemotherapy for patients with Pancreatic cancer liver metastasis. The main purpose of this study is to evaluate the safety and tolerability of Camrelizumab combined with ablation and chemotherapy as a treatment of Pancreatic cancer liver metastasis.